相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。B7-H3: An Attractive Target for Antibody-based Immunotherapy
Filippos Kontos et al.
CLINICAL CANCER RESEARCH (2021)
Antibody-Drug Conjugates: A Comprehensive Review
Puregmaa Khongorzul et al.
MOLECULAR CANCER RESEARCH (2020)
Epigenetic modulations and lineage plasticity in advanced prostate cancer
R. Ge et al.
ANNALS OF ONCOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients
Vincenzo Di Nunno et al.
CLINICAL DRUG INVESTIGATION (2020)
A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer
Amanda E. Hird et al.
CLINICAL GENITOURINARY CANCER (2020)
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
En-Chi Hsu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1)
Wout Oosterheert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
Karim Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
Veronica Mollica et al.
CANCERS (2020)
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
Gaetano Aurilio et al.
CELLS (2020)
High B7-H3 expression is linked to increased risk of prostate cancer progression
Sarah Bonk et al.
PATHOLOGY INTERNATIONAL (2020)
Predicting future cancer burden in the United States by artificial neural networks
Francesco Piva et al.
FUTURE ONCOLOGY (2020)
CD46 and Oncologic Interactions: Friendly Fire against Cancer
Michelle Elvington et al.
ANTIBODIES (2020)
B7-H3 Promotes Prostate Cancer Progression in Mice by Antagonizing Myeloid-Derived Suppressor Cell Apoptosis
Yunfen Zhou et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2020)
Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
Muhammad O. Niaz et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2020)
Metastatic Hormone-Sensitive Prostate Cancer A Review of the Current Treatment Landscape
Emily N. Kinsey et al.
CANCER JOURNAL (2020)
Managing Nonmetastatic Castration-resistant Prostate Cancer
Joaquin Mateo et al.
EUROPEAN UROLOGY (2019)
Treatment of Advanced Prostate Cancer
Min Yuen Teo et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody
Jorge A. Carrasquillo et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Antibody-drug conjugates for cancer
Cindy H. Chau et al.
LANCET (2019)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
E. J. Small et al.
ANNALS OF ONCOLOGY (2019)
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer
Daniel C. Danila et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer
Daniel P. Petrylak et al.
PROSTATE (2019)
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
Wassim Abida et al.
JAMA ONCOLOGY (2019)
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
M. R. Sydes et al.
ANNALS OF ONCOLOGY (2018)
Resistance to Antibody-Drug Conjugates
Sara Garcia-Alonso et al.
CANCER RESEARCH (2018)
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Ekaterina Nevedomskaya et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens
Ines Margarida Gomes et al.
MEDICAL ONCOLOGY (2018)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer
Juniper A. Scribner et al.
CANCER RESEARCH (2018)
Inhibition of Intercellular Communication between Prostate Cancer Cells by A Specific Anti-STEAP-1 Single Chain Antibody
Seyed-Alireza Esmaeili et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2018)
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer
Yang Su et al.
JCI INSIGHT (2018)
177Lu-PSMA Radioligand Therapy for Prostate Cancer
Wolfgang P. Fendler et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The evolution of chemotherapy for the treatment of prostate cancer
D. I. Quinn et al.
ANNALS OF ONCOLOGY (2017)
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
Francesco Massari et al.
TARGETED ONCOLOGY (2016)
AR-V7 and prostate cancer: The watershed for treatment selection?
Chiara Ciccarese et al.
CANCER TREATMENT REVIEWS (2016)
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
Matthew R. Smith et al.
EUROPEAN UROLOGY (2016)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
C. C. Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer
Matthew I. Milowsky et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Immune checkpoint inhibitors and prostate cancer: a new frontier?
Alessandra Modena et al.
ONCOLOGY REVIEWS (2016)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts
Marco Trerotola et al.
ONCOTARGET (2015)
Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives
Matteo Santoni et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Antibody-drug conjugates targeting prostate-specific membrane antigen
William C. Olson et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2014)
Prostate cancer relevant antigens and enzymes for targeted drug delivery
Ashutosh Barve et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Managing bone metastases and reducing skeletal related events in prostate cancer
Benjamin A. Gartrell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Ayesha A. Shafi et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
CD46 in innate and adaptive immunity: an update
J. Cardone et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Phase I trial of the prostate-specific membrane antigen directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
Matthew D. Galsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
